CRTPF - Cardiol Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.3832
+0.1055 (+3.22%)
As of 2:58PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.2777
Open3.3000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.3000 - 3.5400
52 Week Range1.6200 - 10.0000
Volume12,365
Avg. Volume12,798
Market Cap87.078M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cardiol Therapeutics' Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada
    Newsfile

    Cardiol Therapeutics' Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

    Oakville, Ontario--(Newsfile Corp. - January 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that its exclusive manufacturing partner, Dalton Pharma Services ("Dalton"), has received a three-year renewal and license amendment of its Cannabis Act Processing License from Health Canada. This renewal and amendment will ...

  • Newsfile

    Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor

    Oakville, Ontario--(Newsfile Corp. - December 18, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that it has appointed Michael J. Willner, Esq. as Business Advisor to the Company. Mr. Willner has been an active investor for over forty years and is the founder of Willner Capital, Inc., ...

  • Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors
    Newsfile

    Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors

    Oakville, Ontario--(Newsfile Corp. - December 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce the appointment of Mr. Colin Stott to its Board of Directors, effective immediately. Mr. Stott is the former Scientific Affairs Director, International and R&D Operations Director for GW Pharmaceuticals plc ("GW Pharma"), ...

  • Newsfile

    Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

    Oakville, Ontario--(Newsfile Corp. - November 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol ("CBD") products and in the development of innovative cannabidiol medicines for heart disease, commented on Purisys, LLC's news release issued on November 21st which states that the U.S. Drug Enforcement Agency ("DEA") has removed their cannabinoid ingredients from Schedule I of the Controlled Substances Act ("CSA"). Purisys, ...

  • Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100
    Newsfile

    Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100

    Oakville, Ontario--(Newsfile Corp. - November 19, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) products and in the development of innovative cannabidiol medicines for heart disease, is pleased to announce the formation of the Clinical Steering Committee ("CSC") for a Phase 2 international trial in acute myocarditis using the Company's CardiolRx™100 cannabidiol formulation. The CSC, which comprises key opinion leaders ...

  • Newsfile

    Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100

    Oakville, Ontario--(Newsfile Corp. - October 1, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical CBD products and in the development of innovative CBD medicines for heart disease, announces that it has completed the manufacturing scale-up for commercialization of its CardiolRx™100 CBD formulation. CardiolRx 100 (100 mg/mL CBD with 3,000 mg of CBD per bottle) is designed to be the safest and ...

  • Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?
    Simply Wall St.

    Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • PR Newswire

    Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , Sept. 16, 2019 /PRNewswire/ -- Virtual Investor Conferences ...

  • CNW Group

    /R E P E A T -- Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12th/

    /R E P E A T -- Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12th/

  • PR Newswire

    Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12th

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Sept. 6, 2019 /PRNewswire/ -- Virtual Investor Conferences and KCSA Strategic Communications ...

  • CNW Group

    /C O R R E C T I O N from Source -- VirtualInvestorConferences.com/

    /C O R R E C T I O N from Source -- VirtualInvestorConferences.com/

  • Newsfile

    Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th

    Oakville, Ontario--(Newsfile Corp. - September 5, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in producing the purest pharmaceutical CBD products and developing innovative therapies for heart disease, today announced that David Elsley, President & Chief Executive Officer, will present live at the KCSA Cannabis Investor Conference at VirtualInvestorConferences.com on Thursday, September 12th. Date: Thursday, September 12thTime: 12:00 - 12:30 PM ETLink: ...

  • Newsfile

    Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference

    Oakville, Ontario--(Newsfile Corp. - July 25, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), focused on producing pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure, announces today that David Elsley, President and CEO of Cardiol, will be presenting at the Canaccord Genuity 39th Annual Growth Conference being held August 7-8, 2019 at the InterContinental Boston, MA. For two ...

  • CNW Group

    Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing

    Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing

  • CNW Group

    Grit Capital's Live-Stream Virtual Investor Conference June 26th

    Grit Capital's Live-Stream Virtual Investor Conference June 26th

  • Newsfile

    Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation

    Oakville, Ontario--(Newsfile Corp. - June 20, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation.CardiolRx is Cardiol's pure pharmaceutically-produced CBD. Designed to be the safest and most consistent formulation on the ...

  • Newsfile

    Cardiol Therapeutics Reports Results of its AGM

    Oakville, Ontario--(Newsfile Corp. - June 13, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for heart disease, announces results from its Annual General Meeting ("AGM") of shareholders held in Toronto, Ontario, on June 12, 2019. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.Resolutions proposed and approved at the AGM ...

  • Newsfile

    Cardiol Therapeutics to Webcast Annual General Meeting on June 12

    Oakville, Ontario--(Newsfile Corp. - June 10, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, is pleased to announce that it will be webcasting the informal portion of its annual general meeting (AGM) being held at Vantage Venues, 150 King Street West, 27th Floor, Toronto, on June 12, 2019, at 9:00 a.m. ...

  • PR Newswire

    Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on June 4ᵗʰ

    OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical CBD and targeted therapies for inflammatory diseases, announces that David Elsley, President and CEO of Cardiol, will present live at VirtualInvestorConferences.com on June 4th. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

  • Newsfile

    Cardiol Therapeutics' Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD

    Addresses Need for Improved Standards and Regulations Oakville, Ontario--(Newsfile Corp. - June 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for inflammatory diseases, announces that Noramco, Inc. (Noramco) of Wilmington, Delaware, Cardiol's pharmaceutical partner and manufacturer of its pure pharmaceutical CBD, was selected to present at the Food and Drug Administration's (FDA) Scientific Data ...